Juno Therapeutics, Inc. (NASDAQ:JUNO) had its price objective raised by stock analysts at Maxim Group from $34.00 to $56.00 in a research report issued to clients and investors on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price would indicate a potential upside of 28.41% from the company’s current price.

JUNO has been the topic of a number of other research reports. Leerink Swann reiterated an “outperform” rating on shares of Juno Therapeutics in a report on Monday, June 12th. Vetr upgraded Juno Therapeutics from a “strong sell” rating to a “sell” rating and set a $25.50 price target on the stock in a research note on Monday, August 14th. Zacks Investment Research downgraded Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 28th. Morgan Stanley restated an “equal weight” rating and issued a $43.00 price target (up previously from $27.00) on shares of Juno Therapeutics in a research note on Friday. Finally, Raymond James Financial, Inc. upgraded Juno Therapeutics from a “market perform” rating to an “outperform” rating and set a $45.00 price target on the stock in a research note on Tuesday, August 29th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $37.83.

Shares of Juno Therapeutics (NASDAQ:JUNO) opened at 43.61 on Monday. The firm’s market cap is $4.57 billion. Juno Therapeutics has a 1-year low of $17.52 and a 1-year high of $47.03. The company’s 50-day moving average price is $40.64 and its 200 day moving average price is $29.40.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.24). Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm had revenue of $21.30 million for the quarter, compared to analysts’ expectations of $15.59 million. During the same quarter last year, the company posted ($0.64) EPS. The firm’s revenue was down 22.8% on a year-over-year basis. On average, analysts predict that Juno Therapeutics will post ($3.12) EPS for the current year.

WARNING: “Maxim Group Increases Juno Therapeutics, Inc. (JUNO) Price Target to $56.00” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://theolympiareport.com/2017/10/09/maxim-group-increases-juno-therapeutics-inc-juno-price-target-to-56-00.html.

In other news, insider Sunil Agarwal sold 7,285 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total transaction of $326,076.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard Klausner sold 12,000 shares of the stock in a transaction on Monday, August 7th. The shares were sold at an average price of $30.34, for a total value of $364,080.00. Following the transaction, the director now directly owns 788,985 shares in the company, valued at $23,937,804.90. The disclosure for this sale can be found here. Insiders have sold a total of 8,085,004 shares of company stock worth $219,551,561 over the last three months. Insiders own 15.26% of the company’s stock.

Large investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its stake in shares of Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 228 shares in the last quarter. Pacad Investment Ltd. purchased a new stake in shares of Juno Therapeutics in the 2nd quarter worth $105,000. QS Investors LLC purchased a new stake in shares of Juno Therapeutics in the 2nd quarter worth $135,000. Great West Life Assurance Co. Can increased its stake in shares of Juno Therapeutics by 80.5% in the 1st quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 3,800 shares in the last quarter. Finally, Macquarie Group Ltd. purchased a new stake in shares of Juno Therapeutics in the 2nd quarter worth $248,000. Hedge funds and other institutional investors own 67.38% of the company’s stock.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.